2025-06-17
Realheart Receives Patent Approval in the US
Västerås, Sweden, June 17, 2025 – Scandinavian Real Heart AB (publ) announces today that the company has been granted patent approval by the United States Patent and Trademark Office (USPTO) concerning the core technology of Realheart® TAH. The same patent has previously been approved in the European Patent Office (EPO).
The newly approved patent (US patent no. 12318603 B2) covers the key technology of Realheart® TAH, the only artificial four-chamber heart that mimics the physiology of the natural human heart. These unique product features provide completely new opportunities to save lives and give patients a good quality of life while waiting for a heart transplant. The structural design may provide important benefits, e.g., a reduced risk of stroke, bleeding, and anemia – common side effects seen with treatments using currently approved artificial heart devices.
The patent approval confers market protection for the device in the US until 2037.